In her role as Chief Strategy and Business Operations Officer, Fanny guides Foghorn Therapeutics’ corporate strategy, business development, alliance management, program leadership, commercial development, communication, and operations. She brings over 15 years of international healthcare experience across multiple disease areas and stages of drug development and commercialization.
Prior to joining the company, Fanny held various roles at Biogen, including head of multiple sclerosis portfolio strategy and head of launch excellence. Most recently, she was the global commercial development lead for Biogen’s neurodegeneration therapeutic area. In this role, she was responsible for the launch preparation for aducanumab in Alzheimer’s disease, market development, commercial alliances, and new product planning for multiple assets in preclinical and clinical stages.
Before joining Biogen, Fanny spent 10 years advising executive teams of international biopharmaceutical companies as an associate partner at McKinsey & Company in London, where she co-led the firm’s European pharmaceutical launch practice. During her time at McKinsey, Fanny led over 50 teams to support more than 10 drug launches, designed over 10 corporate, business development and product strategies, and supported multiple organizational designs and partnerships.
Fanny earned her master’s degree in business administration from HEC in France, where she graduated with high honors.